冠心病患者经皮冠状动脉介入术后支架内再狭窄危险因素的研究进展  

Research Progress in Risk Factors of In-stent Restenosis in Patients with Coronary Heart Disease after Percutaneous Coronary Intervention

作　　者：张珂瑞 李勇[2] ZHANG Kerui;LI Yong(Medical College of Jiangsu University,Zhenjiang 212000,China;Department of Cardiology,Wujin Hospital Affiliated to Jiangsu University,Changzhou 213000,China)

机构地区：[1]江苏大学医学院,江苏镇江212000 [2]江苏大学附属武进医院心内科,江苏常州213000

出　　处：《医学综述》2022年第1期105-111,共7页Medical Recapitulate

基　　金：江苏省自然科学基金(BK20140249);江苏省青年医学重点人才培养工程(QNRC2016311);常州市高层次卫生人才培养工程(2016CZBJ052);常州市科技局应用基础研究计划(CJ20179004)。

摘　　要：经皮冠状动脉介入(PCI)是目前治疗冠心病的重要手段之一,而支架内再狭窄(ISR)已成为影响PCI疗效的主要因素。ISR是一个复杂的病理生理过程,其发生是患者自身相关因素、冠状动脉病变特点相关因素、介入相关因素和遗传相关因素等作用引起内皮损伤及功能失调,导致病理性内膜增生,但具体机制尚不明确,且缺乏标准化治疗策略。降低ISR的发生率需要积极预防并控制相关危险因素,也亟待医患双方的共同重视以及分子生物学、科技、药物和介入治疗等领域的进一步发展。Percutaneous coronary intervention(PCI)is currently one of the most important methods for the treatment of coronary heart disease,and in-stent restenosis(ISR)has become a dominant factor restricting the efficacy of PCI.The occurrence of ISR is caused by the patient-related factors,coronary-artery-disease-characteristics-related factors,intervention-related factors,and genetic-related factors.These factors cause endothelial damage and dysfunction,leading to pathological intimal hyperplasia.ISR involves complex pathophysiological process although the specific mechanism is not clear.and there is a lack of standardized treatment strategies for ISR.Reducing the incidence of ISR requires active prevention and control of related risk factors,which also urgently requires the joint attention of both doctors and patients,as well as the further development of molecular biology,technology,medicine and interventional therapy.

关 键 词：冠心病 经皮冠状动脉介入 支架内再狭窄 危险因素 

分 类 号：R543.3[医药卫生—心血管疾病]